A cross-sectional survey on the psychological impact of the COVID-19 pandemic on inflammatory bowel disease patients in Saudi Arabia

Mosli, Mahmoud; Alourfi, Mansour; Alamoudi, Amani; Hashim, Almoutaz; Saadah, Omar I.; Sulais, Eman Al; AlAmeel, Turki; Alharbi, Othman; Bakari, Shakir; Meeralam, Yaser; Alshobai, Seigha; Alsahafi, Majid; Jawa, Hani; Qari, Yousef

doi:10.4103/sjg.sjg_220_20

Cited by 38 publications

(53 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According with recent study [10] we confirmed that IBD patients have a high level of anxiety during Covid-19 pandemic. However, no variable other than an increasing age has been shown to be independently associated with this findings.…”

Section: Discussionsupporting

confidence: 71%

See 1 more Smart Citation

COVID-19 and Inflammatory Bowel Disease: Patient Knowledge and Perceptions in a Single Center Survey

et al. 2020

View full text Add to dashboard Cite

Background and objectives: Spreading of SARS-CoV-2 infection from China to countries with a higher prevalence of inflammatory bowel disease (IBD) has generated concern among gastroenterologists and patients. The aim of this survey is to evaluate knowledge about clinical importance of COVID-19, disease management, prevention measures, and anxiety level during pandemic among patients with IBD. Material and methods: From 15th March to 15th April 2020, a questionnaire survey was administered to 200 patients with IBD by email or phone application. The questionnaire consisted of five sections: (1) anthropometric, demographic and clinical characteristics, (2) knowledge about clinical importance of COVID-19, (3) IBD management, (4) prevention measures, (5) anxiety level during pandemic. Results: One hundred forty two questionnaires were completed. Ninety-seven patients (68.3%) were males with a mean age of 46 years (SD 13; range 17–76). Fifty-four individuals (38%) were affected by Crohn disease and 88 (62%) by Ulcerative Colitis. Most patients reported high knowledge about clinical importance of COVID-19 (80%), IBD management (72%), and prevention measures (97%). Sixty-two percent of them showed moderate-high level of anxiety. High education level was independently associated with high knowledge about clinical importance of COVID-19 (odds ratio [OR] 5, 95% confidence interval [CI] 1.49–16.6, p = 0.009) and older age (OR 1, 95%, CI 1.01–1.1, p = 0.01), while the receipt of e-format educational material with low knowledge about clinical importance of COVID-19 (OR 3, 95%, CI 1.08–9.3, p = 0.03). Displaying an active disease appeared to be independently associated with low knowledge of IBD management (OR 5.8, 95% CI 1.4–22.8, p = 0.01) and no variables other than an older age was independently associated with higher level of anxiety (OR 1.04, 95% CI 1.009–1.09, p = 0.01). Conclusions: High educational level and aging promote knowledge about clinical importance of COVID-19, while e-format educational material does not. Taken together with findings that an active disease status compromises knowledge of IBD management and the high level of anxiety related to increasing age, these data suggest the need of further supporting patient-oriented strategies in IBD during Covid-19 pandemic.

show abstract

Section: Discussionsupporting

confidence: 71%

“…Actually, various studies evaluated the anxiety level in general population during pandemic. A Cross-Sectional Survey on the Psychological Impact of the COVID-19 on patients with IBD has shown that about half (48%) expressed symptoms of anxiety [10].…”

Section: Introductionmentioning

confidence: 99%

COVID-19 and Inflammatory Bowel Disease: Patient Knowledge and Perceptions in a Single Center Survey

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Table 1 provides the details of the included studies including location, number of subjects, age, basis of diagnosis, comorbidities and the eventual inclusion in one of the two analyses. 2, The definitions used for COVID diagnosis were based on real time polymerase chain reaction (RT-PCR) testing or clinical symptoms consistent with COVID-19 with radiological evidence of pneumonia in most studies (Table 1). Supplementary Table 2 lists the reasons for the exclusion of studies.…”

Section: Resultsmentioning

confidence: 99%

“…The DerSimonian-Laird estimator was used for computing the tau. 2 We used a random effect approach irrespective of I 2 considering that heterogeneity was present among the studies at the level of study design and approach towards the research question. We calculated the pooled incidence of COVID-19 infection in patients with IBD and in the general population.…”

Section: Discussionmentioning

confidence: 99%

Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: A systematic review and meta‐analysis

et al. 2021

View full text Add to dashboard Cite

Background The risk of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection and clinical outcomes of coronavirus disease (COVID-19) in inflammatory bowel disease are unclear. Methods We searched PubMed and Embase with the keywords: inflammatory bowel disease, Crohn’s disease, ulcerative colitis and COVID-19, novel coronavirus and SARS-CoV-2. We included studies reporting the frequency of COVID-19 infection and outcomes (hospitalisation, need for intensive care unit care and mortality) in patients with inflammatory bowel disease. We estimated the pooled incidence of COVID-19 in inflammatory bowel disease and comparative risk vis-a-vis the general population. We also estimated the pooled frequency of outcomes and compared them in patients who received and did not receive drugs for inflammatory bowel disease. Results Twenty-four studies were included. The pooled incidence rate of COVID-19 per 1000 patients of inflammatory bowel disease and the general population were 4.02 (95% confidence interval (CI) 1.44–11.17) and 6.59 (3.25–13.35), respectively, with no increase in relative risk (0.47, 0.18–1.26) in inflammatory bowel disease. The relative risk of the acquisition of COVID-19 was not different between ulcerative colitis and Crohn’s disease (1.03, 0.62–1.71). The pooled proportion of COVID-19-positive inflammatory bowel disease patients requiring hospitalisation and intensive care unit care was 27.29% and 5.33% while pooled mortality was 4.27%. The risk of adverse outcomes was higher in ulcerative colitis compared to Crohn’s disease. The relative risks of hospitalisation, intensive care unit admission and mortality were lower for patients on biological agents (0.34, 0.19–0.61; 0.49, 0.33–0.72 and 0.22, 0.13–0.38, respectively) but higher with steroids (1.99, 1.64–2.40; 3.41, 2.28–5.11 and 2.70, 1.61–4.55) or 5-aminosalicylate (1.59, 1.39–1.82; 2.38, 1.26–4.48 and 2.62, 1.67–4.11) use. Conclusion SARS-CoV-2 infection risk in patients with inflammatory bowel disease is comparable to the general population. Outcomes of COVID-19-positive inflammatory bowel disease patients are worse in ulcerative colitis, those on steroids or 5-aminosalicylates but outcomes are better with biological agents.

show abstract

“…Female patients, patients educated up to a high school diploma and those with indeterminate colitis were more likely to develop anxiety. 44 Another considerable issue is linked to pediatric disease and therapeutic compliance. A recent report detected preliminary consequences related to COVID-19 lockdown in IBD children.…”

Section: The Decaloguementioning

confidence: 99%

Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase

Papa

Lopetuso

et al. 2020

Therap Adv Gastroenterol

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has raised several concerns for patients with chronic immune-mediated diseases, including inflammatory bowel disease (IBD). As the outbreak appears to be in the descending phase, at least in some part of the world, as in most European countries, guidance is urgently needed to provide optimal care for our IBD patients in order to gradually and safely reduce the gap in care that has been accumulated in the months of lockdown and to face all the backlogs. Therefore, we have provided a decalogue of practical recommendations for gastroenterologists to manage patients with IBD in the post-peak phase of the COVID-19 pandemic. They include all the aspects of IBD care, not only pharmacological ones but also endoscopy, surgery, psychological treatment, telemedicine, diagnostics and educational tasks provided by doctors and patient associations.

show abstract

A cross-sectional survey on the psychological impact of the COVID-19 pandemic on inflammatory bowel disease patients in Saudi Arabia

Cited by 38 publications

References 22 publications

COVID-19 and Inflammatory Bowel Disease: Patient Knowledge and Perceptions in a Single Center Survey

COVID-19 and Inflammatory Bowel Disease: Patient Knowledge and Perceptions in a Single Center Survey

Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: A systematic review and meta‐analysis

Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase

Contact Info

Product

Resources

About